Literature DB >> 21846822

Prognostic and predictive impact of intra- and peritumoral immune infiltrates.

Wolf Herman Fridman1, Jérôme Galon, Franck Pagès, Eric Tartour, Catheriné Sautès-Fridman, Guido Kroemer.   

Abstract

Leukocyte infiltrates into or around tumor cell nests are found in the context of protumorigenic inflammation and anticancer immunosurveillance. Hence, the detailed composition, density, architecture, and function of leukocyte infiltrates must be analyzed to understand their prognostic impact. The ectopic presence within tumors of high endothelial venule cells, which are normally characteristic for secondary lymphoid organs, correlates with a more pronounced infiltration by T lymphocytes and has a positive predictive impact on local advanced breast cancer treated with neoadjuvant chemotherapy. Recent progress in the field indicates that immune infiltrates of the primary tumors, as well as of metastases, are not only independent prognostic biomarkers but can also constitute predictive factors, suggesting that the pretherapeutic immune response can determine the efficacy of conventional chemotherapies. Moreover, accumulating evidence indicates that chemotherapy can stimulate anticancer immune responses coupled with an increased intratumoral lymphoid infiltration, which correlates with tumor mass reduction and patient survival. Improved methods for the automation of immunohistochemistry and digitalized image analyses will pave the way to an improved understanding of the complex interplay between cancer parenchyma, stroma, and immune effectors, as well as to the routine evaluation of immune-related parameters to the clinical management of cancer patients. ©2011 AACR.

Entities:  

Mesh:

Year:  2011        PMID: 21846822     DOI: 10.1158/0008-5472.CAN-11-1316

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  161 in total

1.  Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.

Authors:  Shawn M Jensen; Christopher G Twitty; Levi D Maston; Paul A Antony; May Lim; Hong-Ming Hu; Ulf Petrausch; Nicholas P Restifo; Bernard A Fox
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

2.  Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.

Authors:  Guido H Jajamovich; Chandni R Valiathan; Razvan Cristescu; Sangeetha Somayajula
Journal:  J Neurooncol       Date:  2016-07-08       Impact factor: 4.130

3.  PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.

Authors:  Jan Budczies; Gunhild Mechtersheimer; Carsten Denkert; Frederick Klauschen; Sadaf S Mughal; Priya Chudasama; Michael Bockmayr; Korinna Jöhrens; Volker Endris; Amelie Lier; Felix Lasitschka; Roland Penzel; Manfred Dietel; Benedikt Brors; Stefan Gröschel; Hanno Glimm; Peter Schirmacher; Marcus Renner; Stefan Fröhling; Albrecht Stenzinger
Journal:  Oncoimmunology       Date:  2017-01-27       Impact factor: 8.110

4.  DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

Authors:  Jana Jeschke; Martin Bizet; Christine Desmedt; Emilie Calonne; Sarah Dedeurwaerder; Soizic Garaud; Alexander Koch; Denis Larsimont; Roberto Salgado; Gert Van den Eynden; Karen Willard Gallo; Gianluca Bontempi; Matthieu Defrance; Christos Sotiriou; François Fuks
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 5.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

Review 6.  Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?

Authors:  Theresa L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2013-11-10       Impact factor: 6.968

7.  Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

Authors:  Rafael Carretero; Ibrahim M Sektioglu; Natalio Garbi; Oscar C Salgado; Philipp Beckhove; Günter J Hämmerling
Journal:  Nat Immunol       Date:  2015-04-27       Impact factor: 25.606

Review 8.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

9.  Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.

Authors:  Satoshi Okazaki; Fotios Loupakis; Sebastian Stintzing; Shu Cao; Wu Zhang; Dongyun Yang; Yan Ning; Yu Sunakawa; Stefan Stremitzer; Satoshi Matsusaka; Martin D Berger; Anish Parekh; Jordan D West; Yuji Miyamoto; Mitsukuni Suenaga; Marta Schirripa; Chiara Cremolini; Alfredo Falcone; Volker Heinemann; R William DePaolo; Heinz-Josef Lenz
Journal:  Mol Cancer Ther       Date:  2016-05-11       Impact factor: 6.261

Review 10.  Induced and natural regulatory T cells in human cancer.

Authors:  Theresa L Whiteside; Patrick Schuler; Bastian Schilling
Journal:  Expert Opin Biol Ther       Date:  2012-07-31       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.